Company Search:
Advanced Search
Sponsored Links
Cytokinetics, Inc. Company Snapshot
Cytokinetics, Inc. operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Cytokinetics with three other companies in this sector in the United States: Rigel Pharmaceuticals, Inc. (2015 sales of $28.90 million of which 100% was Contract Revenues), Xencor Inc ($27.76 million of which 100% was Medicine Manufactur), and Cempra Inc ($27.31 million of which 100% was Pharmaceutical Preparations).

Sales Analysis. During the year ended December of 2015, sales at Cytokinetics were $28.66 million. This is a sharp decrease of 38.9% versus 2014, when the company's sales were $46.94 million.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Cytokinetics, Inc.
  Stock Performance Chart for Cytokinetics, Inc.
  Stock Data: Recent Stock Performance:
  Current Price (1/20/2017): 10.60
(Figures in U.S. Dollars)
1 Week -10.5%   13 Weeks -14.5%  
4 Weeks 15.3%   52 Weeks 32.8%  
Cytokinetics, Inc. Key Data:
  Ticker: CYTK Country: United States
  Exchanges: NAS Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2015 Sales 28,658,000
(Year Ending Jan 2016).
Employees: 100
  Currency: U.S. Dollars Market Cap: 429,479,055
  Fiscal Yr Ends: December Shares Outstanding: 40,516,892
  Share Type: Common Closely Held Shares: 7,032,966
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.